Price movement over the last 24 hours
Agilent Technologies Inc vs Microchip Technology Inc. — how do they compare? Agilent Technologies Inc trades at $128.2 (market cap $37.04B), while Microchip Technology Inc. trades at $84.51 (market cap $45.69B). The key difference: Microchip Technology Inc. is the larger of the two by market cap, and Microchip Technology Inc. pays the higher dividend (2.16%). Which is the better fit depends on your goals.
| A | MCHP | |
|---|---|---|
Market Cap | $37.04B | $45.69B |
Sector | Health | Technology |
52-Week High | $157.20 | $102.97 |
52-Week Low | $110.24 | $49.02 |
Enterprise Value | $38.59B | $50.99B |
Dividend Yield | 0.78% | 2.16% |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
Microchip Technology (MCHP) trades at $84.15, down 0.58% on the day, with a bearish technical signal but strong analyst support. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $0.57 exceeding the $0.505 forecast. The company benefits from AI-driven semiconductor demand, aerospace and defense growth, and new product launches like the TimePictra 12 platform. However, 2025 saw a net loss of $500,000 on revenue of $4.40 billion, though 2026 projections indicate a return to profitability with a 4.88% net margin.
MCHP presents a mixed outlook: robust growth catalysts in AI and aerospace contrast with high valuation multiples (P/E of 398.14) and recent profitability challenges. The consensus price target of $115.45 suggests 37% upside, but investors face risks from debt levels and market volatility. The stock's near-term direction hinges on execution of its Q2 2026 earnings and sustained demand in key sectors.
Trailing returns across standard periods
Latest headlines on both assets
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →Microchip became an independent company in 1989 when it was spun off from General Instrument. More than half of revenue comes from MCUs, which are used in a wide array of electronic devices from remote controls to garage door openers to power windows in autos. The company's strength lies in lower-end 8-bit MCUs that are suitable for a wider range of less technologically advanced devices, but the firm has expanded its presence in higher-end MCUs and analog chips as well.
Read more on MCHP →